IGC Stock Forecast: IGC Pharma, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.17
−6.67% on the day

The median 12-month analyst price target for IGC Pharma, Inc. is $6. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 14 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$21.0M
Ticker Nerd rank
14/ 100
Median analyst target
$6.00
Analysts covering
1
Revenue$317K−3.9% y/y
Operating income−$2.5M
Net income−$2.4M
Free cash flow−$1.4M
Quarterly, 7 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.7%
1M
−32.8%
YTD
−40.0%
1Y
−45.8%
From 52W high
−52.0%
From 52W low
0.0%
$0.17
$0.35
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores IGC Pharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
14/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
84
Revisions
57
Momentum
40
Value
25
Accruals
20
Issuance
8
Growth
1
Quality
0

Volatility (84): The share price has been relatively steady.

Quality (0): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

IGC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IGC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00$5.00$6.00Jan 26Apr 26Jul 26Oct 26IGCHigh $6.00Median $6.00Low $6.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1
Buy
0
Hold
0
Sell
$6.00
Low
$6.00
Median
$6.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
26 Aug 2026Ascendiant CapitalMaintainsBuy—
8 June 2026Ascendiant CapitalMaintainsBuy—
8 Apr 2026Ascendiant CapitalMaintainsBuy—
23 Feb 2026Ascendiant CapitalMaintainsBuy—
9 Dec 2025Ascendiant CapitalMaintainsBuy—
26 Aug 2025Ascendiant CapitalMaintainsBuy—
6 Mar 2025Alliance Global PartnersReiteratesBuy—
24 Feb 2025Ascendiant CapitalMaintainsBuy—
5 Dec 2024Ascendiant CapitalMaintainsBuy—
3 Sept 2024Ascendiant CapitalMaintainsBuy—
29 July 2024Ascendiant CapitalMaintainsBuy—
17 July 2024Alliance Global PartnersInitiatesBuy—
21 June 2024Ascendiant CapitalReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for IGC.

Market Radar

This page is one stock. Monday covers all of them.

IGC appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

IGC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, IGC Pharma, Inc. returned −45.8% against +6.9% for the S&P 500, dividends included.

IGC vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120Jan 26Apr 26Jul 26Oct 26IGCS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IGC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
18.1×

Cheaper than 8% of US stocks

Price / book
3.0×

Cheaper than 30% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
17.4%

Higher than 17% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−83.3%

Higher than 15% of US stocks

Return on assets
−50.3%

Higher than 8% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • IGC Pharma, Inc. has a market value of $21.0M and an enterprise value of $21.9M.

  • Revenue in the twelve months to 31 Mar 2026: $1.2M. The latest quarter shrank 3.9% year on year.

  • Net income over the same four quarters: −$6.5M, a −552.1% net margin.

  • Free cash flow in the twelve months to 31 Mar 2026: −$6.8M, after $631K of capital spending.

  • Shares outstanding: 116.7M.

  • IGC Pharma, Inc. employs 70 people — $17K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

IGC and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IGCIGC Pharma, Inc.$21.0M14
RNAZTransCode Therapeutics, Inc.$19.6M12
AARDAardvark Therapeutics, Inc.$20.1M15
ACETAdicet Bio, Inc.$20.5M30
COCPCocrystal Pharma, Inc.$18.3M48
MRKRMarker Therapeutics, Inc.$18.2M76
CVMCEL-SCI Corp.$21.1M38

Take a look at IGC’s peer groups, ranked by the model: consumer staples stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own IGC Pharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about IGC

What is the IGC stock price forecast for 2026-2027?

The median 12-month analyst price target for IGC Pharma, Inc. is $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IGC stock a buy right now?

Of the 1 analyst covering IGC Pharma, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks IGC Pharma, Inc. 14 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IGC?

As at 21 Nov 2026, IGC Pharma, Inc. ranks 14 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (84 of 100).

Will IGC stock go up?

No one can know that. What the data says: the median 12-month target from 1 analyst is $6, and Ticker Nerd's factor model ranks IGC Pharma, Inc. 14 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IGC stock forecast for 2030?

No analyst covering IGC Pharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IGC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $6 over the next 12 months.

How has IGC stock performed over the past year?

IGC Pharma, Inc. returned -45.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does IGC Pharma, Inc. do?

IGC Pharma, Inc. is a clinical-stage biotechnology company focused on developing therapies for Alzheimer’s disease and related neurodegenerative conditions. Its current pipeline centers on IGC-AD1, a cannabinoid-based investigational treatment for agitation in dementia associated with Alzheimer’s disease, alongside preclinical programs such as TGR-63 and other compounds targeting Alzheimer’s-related pathology and metabolic dysfunction.

Company

About IGC Pharma, Inc.

IGC Pharma, Inc. is a clinical-stage biotechnology company focused on developing therapies for Alzheimer’s disease and related neurodegenerative conditions. Its current pipeline centers on IGC-AD1, a cannabinoid-based investigational treatment for agitation in dementia associated with Alzheimer’s disease, alongside preclinical programs such as TGR-63 and other compounds targeting Alzheimer’s-related pathology and metabolic dysfunction. The company also develops AI-enabled tools, including MINT-AD and related healthcare applications, to support risk assessment, research, and clinical decision-making in cognitive disorders. IGC Pharma operates in the pharmaceutical and biotechnology sectors, with activities spanning drug discovery, clinical research, and the development of cannabinoid-based formulations for neurological and metabolic indications. Headquartered in Potomac, Maryland, the company serves the broader life sciences market through its focus on innovative treatments and technology-driven support tools for patients, caregivers, and healthcare providers.

CEO Mr. Ram Mukunda · 70 employees · United States · https://igcpharma.com